Evidence map›Paper›PMID 32252311›Full record

ArticleCells2020

Modulation of STAT3 Signaling, Cell Redox Defenses and Cell Cycle Checkpoints by β-Caryophyllene in Cholangiocarcinoma Cells: Possible Mechanisms Accounting for Doxorubicin Chemosensitization and Chemoprevention.

Antonella Di Sotto, Silvia Di Giacomo, Elisabetta Rubini, Alberto Macone, Marco Gulli, Caterina Loredana Mammola, Margherita Eufemi, Romina Mancinelli, Gabriela Mazzanti

Open access · goldAbstract read
In one paragraph

Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Poly(d,l-lactide-ACS applied bio materials · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Molecules (Basel, Switzerland) · 2022
    Article
  16. Article
  17. Article
  18. Patient-Derived Organoids of Cholangiocarcinoma.International journal of molecular sciences · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Antonella Di SottoDepartment of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0002-7467-1689
Silvia Di GiacomoDepartment of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0003-3049-6644
Elisabetta RubiniDepartment of Biochemical Science "A. Rossi Fanelli", Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0002-1596-5740
Alberto MaconeDepartment of Biochemical Science "A. Rossi Fanelli", Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0003-0455-1400
Marco GulliDepartment of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.
Caterina Loredana MammolaDepartment of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0001-9221-3932
Margherita EufemiDepartment of Biochemical Science "A. Rossi Fanelli", Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0001-9153-972X
Romina MancinelliDepartment of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0003-2040-0581
Gabriela MazzantiDepartment of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiocarcinoma (CCA) is an aggressive group of biliary tract cancers, characterized by late diagnosis, low effective chemotherapies, multidrug resistance, and poor outcomes. In the attempt to identify new therapeutic strategies for CCA, we studied the antiproliferative activity of a combination between doxorubicin and the natural sesquiterpene β-caryophyllene in cholangiocarcinoma Mz-ChA-1 cells and nonmalignant H69 cholangiocytes, under both long-term and metronomic schedules. The modulation of STAT3 signaling, oxidative stress, DNA damage response, cell cycle progression and apoptosis was investigated as possible mechanisms of action. β-caryophyllene was able to synergize the cytotoxicity of low dose doxorubicin in Mz-ChA-1 cells, while producing cytoprotective effects in H69 cholangiocytes, mainly after a long-term exposure of 24 h. The mechanistic analysis highlighted that the sesquiterpene induced a cell cycle arrest in G2/M phase along with the doxorubicin-induced accumulation in S phase, reduced the γH2AX and GSH levels without affecting GSSG. ROS amount was partly lowered by the combination in Mz-ChA-1 cells, while increased in H69 cells. A lowered expression of doxorubicin-induced STAT3 activation was found in the presence of β-caryophyllene in both cancer and normal cholangiocytes. These networking effects resulted in an increased apoptosis rate in Mz-ChA-1 cells, despite a lowering in H69 cholangiocytes. This evidence highlighted a possible role of STAT3 as a final effector of a complex network regulated by β-caryophyllene, which leads to an enhanced doxorubicin-sensitivity of cholangiocarcinoma cells and a lowered chemotherapy toxicity in nonmalignant cholangiocytes, thus strengthening the interest for this natural sesquiterpene as a dual-acting chemosensitizing and chemopreventive agent.

Indexed as

Cell Cycle CheckpointsChemopreventionCholangiocarcinomaDoxorubicinHumansMolecular StructureOxidation-ReductionPolycyclic SesquiterpenesSignal TransductionSTAT3 Transcription FactorcaryophylleneDoxorubicinPolycyclic SesquiterpenesSTAT3 protein, humanSTAT3 Transcription Factorapoptosiscaryophyllane sesquiterpenescell cycle checkpointchemopreventioncholangiocytesgenoprotective effectsGSH depletionH2AX phosphorylationliver cancermetronomic scheduleSTAT3 signaling

Identifiers

PMID32252311
PMCPMC7226839
OpenAlexW3014695187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.